selexipag sold brand name uptravi medication developed actelion treatment pulmonary arterial hypertension selexipag active metabolite free carboxylic acid agonists prostacyclin receptor leads vasodilation pulmonary taken mouth administered common side effects include headache diarrhea nausea vomiting jaw pain myalgia muscle pain pain limbs arthralgia joint pain available generic selexipag indicated treatment pulmonary arterial european union use selexipag together strong inhibitors liver enzyme gemfibrozil contraindicated increases concentrations selexipag twofold active metabolite potentially leading adverse adverse effects selexipag similar intravenous prostacyclins used pulmonary arterial hypertension common side effects include headache jaw pain increased risk hyperthyroidism also noted people taking selexipag active metabolite act prostacyclin receptor lung tissue latter potent selective prostacyclin receptor binding receptor leads three major effects increased vasodilation arteries decreased cell proliferation inhibition platelet beneficial treatment pulmonary arterial hypertension selexipag quickly absorbed gut hydrolyzed intestines liver carboxylesterases absolute bioavailability likely high firstpass effect highest concentrations blood plasma reached one three hours selexipag three four hours active metabolite circulation substances bound plasma proteins namely albumin glycoprotein equal liver enzymes lesser extent hydroxylate dealkylate active substance thereby inactivating besides glucuronidized enzymes terminal halflife selexipag hours active metabolite synthesis celexipag begins two inexpensive compounds glycine hydrochloride benzil condensed basic us food drug administration fda granted selexipag orphan drug designation pulmonary arterial treatment chronic thromboembolic pulmonary approved fda december european union drug approved may expected price drug us per patient httpsenwikipediaorgwikiselexipag